BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19606088)

  • 1. Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics.
    Braun F; Schöcklmann H; Ziegler E; Kunzendorf U; Armstrong VW; Renders L
    Clin Pharmacol Ther; 2009 Oct; 86(4):411-5. PubMed ID: 19606088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.
    Greanya ED; Poulin E; Partovi N; Shapiro RJ; Al-Khatib M; Ensom MH
    Am J Health Syst Pharm; 2012 Jan; 69(2):134-42. PubMed ID: 22215359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients.
    Mino Y; Naito T; Otsuka A; Ushiyama T; Ozono S; Kagawa Y; Kawakami J
    Clin Biochem; 2009 May; 42(7-8):595-601. PubMed ID: 19100248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.
    Rogers CC; Alloway RR; Alexander JW; Cardi M; Trofe J; Vinks AA
    Clin Transplant; 2008; 22(3):281-91. PubMed ID: 18482049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients.
    Shipkova M; Armstrong VW; Weber L; Niedmann PD; Wieland E; Haley J; Tönshoff B; Oellerich M;
    Ther Drug Monit; 2002 Jun; 24(3):390-9. PubMed ID: 12021631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB; Hamad I; Zuckerman S; Zhang S; Warty VS; Fung JJ; Venkataramanan R
    Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase.
    Mino Y; Naito T; Otsuka A; Takayama T; Ozono S; Kagawa Y; Kawakami J
    J Clin Pharm Ther; 2011 Apr; 36(2):217-24. PubMed ID: 21366651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG; Harmon M; Gohh RY; Akhlaghi F
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ann Pharmacother; 2006 Sep; 40(9):1509-16. PubMed ID: 16882870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
    Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.